{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-02T18:59:57.240905+00:00","company":{"ticker":"BICX","cik":1443863,"company_name":"BioCorRx Inc."},"pagination":{"limit":100,"returned":12,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"LGH Investments, LLC","detail":"equity_purchase","count":1,"first_seen":"2023-11-16T23:59:59+00:00","last_seen":"2023-11-16T23:59:59+00:00","evidence_fact_ids":[92576]},{"display_name":"Lourdes Felix, Louis C Lucido, and Kent Emry","detail":"equity_purchase","count":1,"first_seen":"2026-04-02T23:59:59+00:00","last_seen":"2026-04-02T23:59:59+00:00","evidence_fact_ids":[25997]}]},"facts":[{"fact_type":"material_agreement","fact_key":"ff50b2324c0c9c2ca3f2c0f396104f963c43ae6a","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2026-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"equity_purchase","counterparty":"Lourdes Felix, Louis C Lucido, and Kent Emry","effective_date":"2026-03-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"BioCorRx Inc. entered into Agreement with Lourdes Felix, Louis C Lucido, and Kent Emry (effective 2026-03-26).","evidence_excerpt":"On March 26, 2026, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a stock exchange agreement (the “Agreement”) with Lourdes Felix, Chief Executive Officer of the Company and a member of the Company’s Board of Directors (the “Board”), Louis C Lucido, President of the Company and a member of the Board, and Kent Emry (collectively with Lourdes Felix and Louis C Lucido, the “Shareholders”), a member of the Board, pursuant to which the Shareholders agreed to transfer to the Company an aggregate of 1,215 shares of common stock of BioCorRx Pharmaceuticals, Inc., a Nevada corporation, which is a majority-owned subsidiary of the Company (the “Subsidiary”), representing in the aggregate approximately 12.15% of the outstanding common stock of the Subsidiary, in exchange for an aggregate of 2,263,371 shares (the “Parent Shares”) of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001477932-26-001957","anchor_url":"https://secwatch.observer/filing/0001477932-26-001957#claim-ff50b2324c0c9c2ca3f2c0f396104f963c43ae6a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/0001477932-26-001957-index.htm"},{"fact_type":"executive_change","fact_key":"30f84ca032","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-02","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Harsha Murthy resigned as director at BioCorRx Inc..","evidence_excerpt":"Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “ Murthy Resignation ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-24-001846","anchor_url":"https://secwatch.observer/filing/0001477932-24-001846#claim-30f84ca032","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224001846/0001477932-24-001846-index.htm"},{"fact_type":"executive_change","fact_key":"4f6a926472","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-31","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Brady Granier resigned as director at BioCorRx Inc..","evidence_excerpt":"On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “ Board ”) of BioCorRx Inc. (the “ Company ”), effective March 31, 2024 (the “ Granier Resignation ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-24-001846","anchor_url":"https://secwatch.observer/filing/0001477932-24-001846#claim-4f6a926472","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224001846/0001477932-24-001846-index.htm"},{"fact_type":"executive_change","fact_key":"8072501f1b","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-01","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Louis Lucido was appointed as President at BioCorRx Inc..","evidence_excerpt":"On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-24-000065","anchor_url":"https://secwatch.observer/filing/0001477932-24-000065#claim-8072501f1b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/0001477932-24-000065-index.htm"},{"fact_type":"executive_change","fact_key":"a32e32ff1c","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-01-31","interim":false,"role":"President","role_category":"president","successor_name":"Louis Lucido","successor_named":true},"claim":"Brady Granier resigned as President at BioCorRx Inc..","evidence_excerpt":"On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-24-000065","anchor_url":"https://secwatch.observer/filing/0001477932-24-000065#claim-a32e32ff1c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/0001477932-24-000065-index.htm"},{"fact_type":"material_agreement","fact_key":"0ca9bd5091e150ec33130ace8b665337f87d2695","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2023-12-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"an accredited investor","effective_date":"2023-12-08","item_codes_triggered":["1.01"],"value_text":"$200,000"},"claim":"BioCorRx Inc. entered into Securities Purchase Agreement with an accredited investor valued at $200,000 (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with an accredited investor (the “Investor”), whereby the Investor purchased from the Company, for a purchase price of $200,000 (the “Purchase Price”) (i) a promissory note of the Company in the original principal amount of $220,000.00 (the “Note”), (ii) a common stock purchase warrant for 200,000 shares (the “Warrant”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (iii) 24,000 restricted shares of Common Stock (the “Inducement Shares”, and collectively with the Note and Warrant, the “Securities”).","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001477932-23-009154","anchor_url":"https://secwatch.observer/filing/0001477932-23-009154#claim-0ca9bd5091e150ec33130ace8b665337f87d2695","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223009154/0001477932-23-009154-index.htm"},{"fact_type":"material_agreement","fact_key":"445a18411515b37bb9abbde5de6bd88fb18319ae","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2023-11-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"LGH Investments, LLC","effective_date":"2023-11-10","item_codes_triggered":["1.01"],"value_text":"$200,000"},"claim":"BioCorRx Inc. entered into Securities Purchase Agreement with LGH Investments, LLC valued at $200,000 (effective 2023-11-10).","evidence_excerpt":"On November 10, 2023, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with LGH Investments, LLC, a Wyoming limited liability company (the “LGH”), whereby LGH purchased from the Company, for a purchase price of $200,000 (the “Purchase Price”) (i) a promissory note of the Company in the original principal amount of $220,000.00 (the “Note”), (ii) a common stock purchase warrant for 200,000 shares (the “Warrant”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (iii) 24,000 restricted shares of Common Stock (the “Inducement Shares”, and collectively with the Note and Warrant, the “Securities”).","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001477932-23-008570","anchor_url":"https://secwatch.observer/filing/0001477932-23-008570#claim-445a18411515b37bb9abbde5de6bd88fb18319ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223008570/0001477932-23-008570-index.htm"},{"fact_type":"executive_change","fact_key":"134a99e2f4","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"granted paid administrative leave of absence","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Brady Granier changed role as President at BioCorRx Inc..","evidence_excerpt":"On October 30, 2023, the board of directors (the “Board”) of BioCorRx Inc. (the “Company”) approved Brady Granier’s request for a paid administrative leave of absence from his position as the President of the Company for the period between October 30, 2023 and January 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-23-008060","anchor_url":"https://secwatch.observer/filing/0001477932-23-008060#claim-134a99e2f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223008060/0001477932-23-008060-index.htm"},{"fact_type":"material_agreement","fact_key":"1a58f009486177473181b09c5f6eb817a511761a","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2023-04-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Subscription Agreement","agreement_type":"equity_purchase","counterparty":"an accredited investor","effective_date":"2023-04-04","item_codes_triggered":["1.01"],"value_text":"$300,000"},"claim":"BioCorRx Inc. entered into Subscription Agreement with an accredited investor valued at $300,000 (effective 2023-04-04).","evidence_excerpt":"On April 4, 2023, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with an accredited investor (the “Investor”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001477932-23-002411","anchor_url":"https://secwatch.observer/filing/0001477932-23-002411#claim-1a58f009486177473181b09c5f6eb817a511761a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223002411/0001477932-23-002411-index.htm"},{"fact_type":"executive_change","fact_key":"5cdfe19031","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Harsha Murthy was appointed as Director at BioCorRx Inc..","evidence_excerpt":"On January 20, 2023, BioCorRx, Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-23-000474","anchor_url":"https://secwatch.observer/filing/0001477932-23-000474#claim-5cdfe19031","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223000474/0001477932-23-000474-index.htm"},{"fact_type":"auditor_change","fact_key":"5f229217fac43f9516646e1201453f02b966b58d","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2022-10-27T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Marcum LLP","disagreement_text":null,"effective_date":"2022-10-21","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"BioCorRx Inc. engaged Marcum LLP as its auditor.","evidence_excerpt":"the Board of Directors of the Company approved the engagement of Marcum LLP to serve as the independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001477932-22-007951","anchor_url":"https://secwatch.observer/filing/0001477932-22-007951#claim-5f229217fac43f9516646e1201453f02b966b58d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222007951/0001477932-22-007951-index.htm"},{"fact_type":"auditor_change","fact_key":"31eb2220685c93b7be9b4539653cc0fb0c0fa462","cik":1443863,"ticker":"BICX","company_name":"BioCorRx Inc.","filed_at":"2022-10-27T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Friedman LLP","disagreement_text":"no disagreements with Friedman on any matter of accounting principles or practices","effective_date":"2022-10-21","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Marcum LLP"},"claim":"Friedman LLP resigned as auditor of BioCorRx Inc..","evidence_excerpt":"Friedman formally resigned on October 21, 2022, as our independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001477932-22-007951","anchor_url":"https://secwatch.observer/filing/0001477932-22-007951#claim-31eb2220685c93b7be9b4539653cc0fb0c0fa462","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222007951/0001477932-22-007951-index.htm"}]}